Related Experiment Video
Updated: Aug 25, 2025
Immunostaining for DNA Modifications: Computational Analysis of Confocal Images
Published on: September 7, 2017
Blood DNA methylation marks discriminate Chagas cardiomyopathy disease clinical forms
Pauline Brochet1, Barbara Ianni2, João P S Nunes1,2,3,4
1Aix Marseille Univ, TAGC Theories and Approaches of Genomic Complexity, Institut MarMaRa, Marseille, France.
Insights
New DNA methylation biomarkers can predict Chronic Chagas Cardiomyopathy (CCC) occurrence and severity with over 95% accuracy. These biomarkers offer insights into disease mechanisms, aiding in early detection and understanding of Chagas disease progression.
Area of Science:
- Parasitology and Tropical Diseases
- Genetics and Genomics
- Cardiology
Background:
- Chagas disease affects millions globally, with 30% developing chronic forms like Chronic Chagas Cardiomyopathy (CCC) decades post-infection.
- Currently, no effective treatments exist for CCC, which presents in moderate (EF ≥ 0.4) and severe (EF < 0.4) stages.
Purpose of the Study:
- To identify DNA methylation biomarkers for predicting CCC occurrence and stage from blood samples.
- To explore the association of these biomarkers with genes involved in CCC pathogenesis.
Main Methods:
- Machine learning algorithms were employed to analyze DNA methylation data.
- CpG sites (CpGs) were identified as potential biomarkers.
- Validation was performed on a test cohort.
Main Results:
- Two sets of DNA methylation biomarkers demonstrated over 95% accuracy in predicting CCC occurrence and stage.
- Identified CpGs are located near genes implicated in immune response, nervous system, ion transport, and ATP synthesis pathways.
- Some targeted genes showed differential expression in cardiac tissues, highlighting a link between methylation, gene expression, and CCC.
Conclusions:
- DNA methylation biomarkers show significant potential for early diagnosis and staging of Chronic Chagas Cardiomyopathy.
- These biomarkers may serve as indicators of key molecular pathways involved in CCC development, particularly those related to nervous and ionic processes.
Abstract:
Chagas disease is a parasitic disease from South America, affecting around 7 million people worldwide. Decades after the infection, 30% of people develop chronic forms, including Chronic Chagas Cardiomyopathy (CCC), for which no treatment exists. Two stages characterized this form: the moderate form, characterized by a heart ejection fraction (EF) ≥ 0.4, and the severe form, associated to an EF < 0.4. We propose two sets of DNA methylation biomarkers which can predict in blood CCC occurrence, and CCC stage. This analysis, based on machine learning algorithms, makes predictions with more than 95% accuracy in a test cohort. Beyond their predictive capacity, these CpGs are located near genes involved in the immune response, the nervous system, ion transport or ATP synthesis, pathways known to be deregulated in CCCs. Among these genes, some are also differentially expressed in heart tissues. Interestingly, the CpGs of interest are tagged to genes mainly involved in nervous and ionic processes. Given the close link between methylation and gene expression, these lists of CpGs promise to be not only good biomarkers, but also good indicators of key elements in the development of this pathology.
